Research and Markets: Global Hormone Refractory Breast Cancer Pipeline Insights 2016
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/lnhlkf/hormone)
has announced the addition of the “Hormone
Refractory Breast Cancer-Pipeline Insights, 2016″ report to
their offering.
Hormone Refractory Breast Cancer-Pipeline Insights, 2016 provides in
depth insights on the pipeline drugs and their development activities
around the Hormone Refractory Breast Cancer. The report covers the
product profiles in various stages of development including Discovery,
Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.
Report covers the product clinical trials information and other
development activities including technology, licensing, collaborations,
acquisitions, fundings, patent and USFDA & EMA designations details.
The report also provides detailed information on the discontinued and
dormant drugs that have gone inactive over the years for Hormone
Refractory Breast Cancer.
The report also assesses the Hormone Refractory Breast Cancer
therapeutics by Monotherapy, Combination products, molecule type and
Route of Administration.
Scope
-
The report provides competitive pipeline landscape of Hormone
Refractory Breast Cancer -
The report provides pipeline products under drug profile section which
includes product description, MOA, licensors & collaborators,
development partner and chemical information -
Coverage of the Hormone Refractory Breast Cancer pipeline on the basis
of target, MOA, route of administration, technology involved and
molecule type -
The report reviews key players involved in the therapeutics
development for Hormone Refractory Breast Cancer and also provide
company profiling -
The report also gives the information of dormant and discontinued
pipeline projects -
Pipeline products coverage based on various stages of development
ranging from preregistration till discovery and undisclosed stages -
Provides pipeline assessment by monotherapy and combination therapy
products, stage of development and molecule type
Key Topics Covered:
- Hormone Refractory Breast Cancer Overview
- Hormone Refractory Breast Cancer Pipeline Therapeutics
-
Hormone Refractory Breast Cancer Therapeutics under Development by
Companies - Hormone Refractory Breast Cancer Filed and Phase III Products
- Comparative Analysis
- Hormone Refractory Breast Cancer Phase II Products
- Comparative Analysis
- Hormone Refractory Breast Cancer Phase I and IND Filed Products
- Comparative Analysis
-
Hormone Refractory Breast Cancer Discovery and Pre-Clinical Stage
Products - Comparative Analysis
- Drug Candidate Profiles
- Hormone Refractory Breast Cancer – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hormone Refractory Breast Cancer – Discontinued Products
- Hormone Refractory Breast Cancer – Dormant Products
-
Companies Involved in Therapeutics Development for Hormone Refractory
Breast Cancer
For more information visit http://www.researchandmarkets.com/research/lnhlkf/hormone
Contacts
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare
and Medical Devices, Pharmaceuticals